Short Interest in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Increases By 372.7%

Key Points

• Pharming Group N.V. experienced a significant increase in short interest, rising by 372.7% from 1,100 shares to 5,200 shares as of July 31st.
• The company reported $0.06 EPS, surpassing analyst expectations of ($0.10), with quarterly revenue reaching $93.20 million.
• An institutional investor, EverSource Wealth Advisors LLC, purchased 2,979 shares of Pharming Group during the second quarter, valued at approximately $32,000.

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) was the target of a significant increase in short interest in July. As of July 31st, there was short interest totaling 5,200 shares, anincreaseof372.7% from the July 15th total of 1,100 shares. Based on an average trading volume of 5,500 shares, the days-to-cover ratio is presently 0.9 days. Currently,0.0% of the company's stock are sold short. Currently,0.0% of the company's stock are sold short. Based on an average trading volume of 5,500 shares, the days-to-cover ratio is presently 0.9 days.

Institutional Trading of Pharming Group

A hedge fund recently bought a new stake in Pharming Group stock. EverSource Wealth Advisors LLC acquired a new stake in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 2,979 shares of the company's stock, valued at approximately $32,000. Institutional investors own 0.03% of the company's stock.

Pharming Group Stock Down 2.9%

Shares of NASDAQ:PHAR traded down $0.36 during trading on Wednesday, hitting $12.22. The company's stock had a trading volume of 14,047 shares, compared to its average volume of 6,126. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.07 and a current ratio of 2.79. Pharming Group has a fifty-two week low of $6.73 and a fifty-two week high of $17.08. The stock's 50-day moving average price is $10.90 and its two-hundred day moving average price is $9.70. The company has a market capitalization of $837.25 million, a PE ratio of -94.00 and a beta of 0.02.

Pharming Group (NASDAQ:PHAR - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The company reported $0.06 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.16. Pharming Group had a negative return on equity of 3.31% and a negative net margin of 2.19%.The business had revenue of $93.20 million for the quarter, compared to analysts' expectations of $70.36 million. Pharming Group has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Pharming Group will post -0.2 EPS for the current year.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.